Thus, while IP6K1 is a promising potential therapeutic target because of its role in many disease processes such as type 2-diabetes, obesity, mental disorders, metabolic dysfunction, and cancer, therapeutically targeting IP6K1 must consider the complexity of interactions in which it plays a role demanding further comprehensive investigations. Here, IP6K1 is linked to obesity due to melanocortin 4 receptor deficiency.